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Doxycycline reduces MMP-2 activity and
inhibits invasion of 12Z epithelial
endometriotic cells as well as MMP-2 and
-9 activity in primary endometriotic stromal
cells in vitro
Eleftherios P. Samartzis* , Daniel Fink, Manuel Stucki and Patrick Imesch
Abstract
Background: Matrix metalloproteinases (MMPs), especially the gelatinases MMP-2 and MMP-9, play a crucial role in
the pathogenesis of endometriosis by enabling invasion. Doxycycline is a well-tolerated antibiotic and a potent
MMP-inhibitor in subantimicrobial doses.
Methods: Gelatin zymography and activity assays were used to detect latent and active MMP-2 and -9 in cell
culture supernatants of immortalized epithelial (12Z) and two isolates of primary endometriotic stromal cells treated
with doxycycline. The invasiveness of 12Z endometriotic cells treated with doxycycline was assessed in matrigel-
coated invasion chambers. The effect on latent and active MMP-2 expression of the combination of progesterone
and doxycycline was tested in 12Z.
Results: Doxycycline significantly reduced the MMP-2 activity and pro-MMP-2 expression in 12Z and the MMP-2
and -9 activity as well as expression of pro-MMP-2 and -9 in primary endometriotic stromal cells. The percentage of
12Z cells invading through a matrigel-coated membrane was reduced to 65 and 22% of the control after treatment
with doxycycline at doses of 1 μg/ml and 10 μg/ml, respectively. Furthermore, a combination of progesterone and
doxycycline showed an additive effect in low doses on the reduction of MMP-2 activity and pro-MMP2 expression
in 12Z endometriotic cells.
Conclusions: In conclusion, the MMP-inhibiting features of subantimicrobial-dose doxycycline may be further
evaluated as a well-tolerable additional therapeutic approach, e.g. in combination with progestins such as dienogest, in
patients with infiltrative endometriosis with insufficient response to current medical treatment options.
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Background
One of the most important pathogenic characteristics of
the proliferation of endometriosis, especially in the
deep-infiltrating form, is the invasion of endometriotic
cells through the basilar membrane of the peritoneal
mesothelium into the extracellular matrix [1]. Although
surgical resection of endometriotic lesions is the stand-
ard therapeutic approach in symptomatic endometriosis,
recurrence of the disease and its symptoms after surgery
is frequent and often requires repeated surgeries [2].
Treatment strategies of endometriosis associated with
pain are the combination of surgical removal of endome-
triotic lesions followed by a medical prophylaxis for re-
currence. At present, no clinically available medical
compound for the treatment of endometriosis is cytore-
ductive. Therefore, the suppression of new implants
rather than the elimination of existing lesions should be
the goal of any postoperative pharmacological treatment
[3]. Although medical treatment with GnRH analogues
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and more recently with dienogest (a synthetic progestin)
have proven to be efficacious to a certain extent, there
are frequent cases where these therapies are not suffi-
cient to control endometriosis and to prevent a recur-
rence of the disease [4]. Consequently, combinatory
treatments with other compounds may be a promising
option to increase the efficacy of the already available
therapies used against endometriosis and non-hormonal
drugs may be an interesting alternative for patients wish-
ing a non-hormonal medical prevention of a recurrence
of endometriosis which is still yet not available.
Matrix metalloproteinases (MMPs), especially members
of the group of gelatinases (MMP-2 and MMP-9), play a
crucial role in the development of endometriosis, since
MMP-9 has been shown to be increased in eutopic and
ectopic endometrial tissue from women with endometri-
osis and higher levels of MMP-2, − 9, and − 14 mRNA
have been found in endometriotic cells when compared to
normal endometrium [5–7]. Furthermore, the concentra-
tion of MMP-2 has been shown to be significantly ele-
vated in the serum and peritoneal fluid of women with
endometriosis in comparison to healthy women [8]. Con-
sequently MMPs produced by endometriotic cells may de-
grade the extracellular matrix leading to vascularization
and growth of endometriotic lesions and invasion into the
peritoneal layer [9]. The pathogenic role of MMP-9 has
also been demonstrated in endometrial epithelial cells of
patients with endometriosis [10]. Specific inhibitors that
exhibit a similar action to the endogenous antagonists, the
tissue inhibitors of metalloproteinases (TIMPs), such as
ONO-4817, have shown promising results in animal
models in the treatment of e.g. endometriosis uteri
interna, also known as adenomyosis [11]. However, exces-
sive TIMP levels may also be associated with adverse
events leading to reproductive problems [12] and inhibi-
tors similar to endogenous TIMP may therefore not be
suitable for the treatment of endometriosis [13]. However,
the roles and interactions of different MMPs in endomet-
riosis are complex and not yet fully understood [14].
Doxycycline, a well-known antibiotic substance of the
family of the tetracyclines is a well-tolerated drug that
interestingly also possesses strong MMP inhibitory activ-
ity that is already observed at a subantimicrobial dosage
level [15, 16]. This effect was first observed in periodon-
titis research, and clinical studies are investigating its
use as an MMP inhibitor in dermatology, cardiovascular
medicine, ophthalmology and dentistry [16, 17]. The
MMP-inhibiting effect of subantimicrobial-dose doxy-
cycline relies on a direct inhibition of the active form of
MMPs, which is achieved by the binding of calcium and
zinc ions as well as by a direct inhibition of the activa-
tion of latent pro-MMPs [15].
The aim of this study was to investigate if doxycycline
acts as an inhibitor of MMP expression and activity in
endometriotic cells in vitro. Therefore, an immortalized
epithelial endometriotic cell line (12Z), which is widely
used in endometriosis research, and since there was no ac-
cess to an immortalized stromal cell line (e.g. 22B) for the
stromal compartment, primary stromal endometriotic
cells isolated from endometriomas were studied in the ex-
periments. Furthermore, using 12Z in matrigel coated
membranes we studied if doxycycline inhibits the invasion
of endometriotic cells. Moreover, we aimed to investigate
whether a combinatory treatment with low-dose doxycyc-
line and progesterone increases the MMP-inhibiting effect
of these drugs in 12Z endometriotic cells.
Methods
Cell culture
This study was conducted on an immortalized epithelial
endometriotic cell line (12Z) and on two primary stromal
cells freshly isolated from endometriotic tissue as de-
scribed below. Mycoplasma testing of the cultured cells
was carried out on a regular basis during the study and
was repeatedly negative. The primary cell study was ap-
proved by the institutional review board and individual in-
formed consent was obtained by the participants. Only
early passage numbers were used for the experiments (in
12Z: passage 2–5 of the initially received cell line, in pri-
mary stromal cells: passage 2–3 of freshly isolated cells).
Immortalized epithelial endometriotic cell line 12Z
The 12Z endometriotic cell line was kindly provided by
Professor Anna Starzinski-Powitz (Department of Biology,
University of Frankfurt, Frankfurt am Main, Germany).
The cell line was generated through the in situ electropor-
ation of primary peritoneal epithelial endometriotic cells
with SV-40 T-antigen. The characteristics of this cell line
have been previously described [18]. 12Z cells were cul-
tured in Dulbecco’s Modified Eagle Medium (DMEM,
21980; Invitrogen, Basel, Switzerland) containing 10% fetal
bovine serum (Gibco, LifeTechnologies, Waltham, MA,
USA) and 1% antibiotic-antimycotic (containing penicillin,
streptomycin and amphotericin B, Gibco) at 37 °C in an
atmosphere with 5% CO2 and 95% humidity. Experiments
were performed with a cell confluency of 50–70%.
Primary cell cultures
Primary cells were isolated from histologically confirmed
endometriotic tissue of two different patients by the fol-
lowing procedure: Endometriotic tissue samples from
endometriomas were collected freshly in the operating
room and transferred directly to the cell culture lab for
further processing. The diagnosis of endometriosis was
confirmed histologically by a pathologist. The freshly
collected endometriotic tissue was separated from any
connective tissue and then minced in fine slices and in-
cubated for 90 min in a 10mg/ml collagenase solution at
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37 °C (Collagenase C2674, Sigma-Aldrich, Saint Louis,
MO, USA). After this digestion procedure, the suspension
was passed through a 100-μm mesh filter to separate the
cells from any remaining connective tissue. The filtrate
was then collected and passed through a second 40-μm
mesh filter. The flow through, consisting of the stromal
endometriotic cells, was transferred to a plate and cul-
tured under standard culturing conditions in Iscoves
modified medium (IMEM, Gibco) supplemented with
10% fetal bovine serum and 1% antibiotic-antimycotic
(containing penicillin, streptomycin and amphotericin B,
Gibco) in an incubator at 37 °C in an atmosphere of 5%
CO2 and 95% humidity. For the drug treatment experi-
ments cell confluency was 80% at the time point of treat-
ment. Primary epithelial endometriotic cells were not kept
in culture since low cell quantity and proliferation rate did
not allow an adequate MMP quantification in these cells.
As part of a parallel experiment and confirmation of stro-
mal origin of the cells we performed three-dimensional
(3D) cell cultures with the primary stromal cells (not
shown). The cells aggregated to 3D-cell-conglomerates
and we then produced histological slides from the micro-
tissues, which were stained immunohistochemically for
pan-cytokeratin, vimentin, and mib-1. Vimentin showed a
general strong positive staining and pan-cytokeratin
stained ubiquitously negative. Mib-1 stained positive in a
few cells. In addition, some brown pigment was found
which most likely corresponds to blood residues.
Drug treatment
For the drug treatment experiments, 12Z or primary
stromal endometriotic cells were seeded in 6-well
plates at a density of 3 × 105 cells per well for 12Z
and 6 × 105 cells per well for primary stromal cells.
The following day, the medium was replaced by
serum-free medium after washing the cells once with
phosphate-buffered saline. After 24 h the medium
was replaced with 2 ml of serum-free medium con-
taining drugs in the indicated doses. Serum-free
medium was used to avoid foreign protease activity
in the serum as has been done by others [19] and
no signs of reduced cell viability were found as de-
scribed below. Doxycycline (doxycycline hyclate,
Sigma-Aldrich) was purchased and stock solutions
were diluted in sterile water to a concentration of 1
mg/ml and kept in the dark at − 20 °C. Treatment
doses were chosen according to cell culture doses
for human cell lines reported in the literature [20].
Progesterone (Sigma-Aldrich) was stored at − 20 °C
as a stock solution in DMSO at a concentration of
100 mM. Drugs were freshly diluted from the stock
for every treatment. Controls were treated with the
vehicle substance in the same concentration.
Cell viability
Cell viability after treatment with doxycycline was
assessed in parallel to the drug treatment experiments
described above with an automated cell-counting device
(Countess®, Invitrogen, LifeTechnologies, Thermo Fisher
Scientific Inc., Waltham, MA, USA) after trypan blue
staining of the cells to distinguish viable from dead cells.
After the 24 h doxycycline treatment, the supernatants
were collected and adherent cells were trypsinized and
resuspended in the respective supernatants. Ten microli-
ters of the cell suspension were mixed 1:1 with trypan
blue staining and filled into the counting chamber. The
number and fraction of viable cells was determined for
each plate and calculated as percentage of the number
of viable cells in the control plate.
Gelatin zymography
Gelatin zymography was used to detect gelatinases in
the supernatants of treated cells as has been done by
others [19]. Briefly, supernatants of treated cells (a total
of 25 μl per well containing v/v 1:1 of supernatant and
Laemmli buffer) were loaded on a gelatin (type A,
G-8150, Sigma-Aldrich) containing SDS polyacrylamide
gels (acrylamide concentration of 8%) followed by elec-
trophoresis for 6 h. SDS and Triton X-100 were then
washed out of the gels to allow a renaturation of the
MMP proteins. This was followed by incubation for 24 h
(if not specified as prolonged incubation of 36 h) in a
zinc- and calcium-chloride-containing buffer at 37 °C,
allowing gelatin degradation by gelatinases. Gels were
stained with Coomassie blue for 2 h and then destained
for 45 to 90min until bands representing gelatin degrad-
ation by the gelatinases became visible. Reconstituted ly-
ophilized human pro-MMP-2 and pro-MMP-9 were
used as positive controls (contained in Biotrak MMP-2
and MMP-9 activity assays kits, GE Healthcare). The
gelatin zymograms were quantified with the Image-J
software (imagej.nih.gov/ij).
MMP activity assay
Levels of the active form of MMP-2 and MMP-9 were
measured by an activity assay (Biotrak MMP-2 activity
assay and Biotrak MMP-9 activity assay, GE Healthcare)
according to the provided manufacturer’s protocol. Briefly,
supernatants of treated cells were added to the
anti-MMP-2 (respectively anti-MMP-9) precoated micro-
plate wells and incubated overnight at 4 °C in accordance
with the manufacturer’s instructions. The following day,
the plates were rinsed 4 times with the provided washing
buffer and then incubated with the assay buffer in addition
to the substrate and detection reagent. The plates were
analyzed immediately after the addition of the detection
reagent (a dection enzyme that is activated by captured ac-
tive MMP-2 (respectively MMP-9) through a single
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proteolytic event, which can be measured using a specific
chromogenic peptide substrate) for the baseline measure-
ment and again after 3-6 h for signal recording in a spec-
trophotometer (Epoch Microplate Spectrophotometer,
BioTek, Winooski, VT, USA). Standard curves were ob-
tained for each activity assay and were similar to the
standard curve provided by the manufacturer.
Matrigel invasion assay
The matrigel invasion assay was carried out in 24-well
matrigel invasion chambers (BD BioCoat BD Matrigel
Invasion Chamber, Franklin Lakes, New Jersey 07417–
1880). In brief, 12Z endometriotic cells were seeded in
invasion chambers (2.5 × 104 cells per 24-well invasion
chamber) in serum-free medium containing the indi-
cated doses of doxycycline. Serum-containing medium
(DMEM containing 10% fetal bovine serum) was added
to the lower chamber as a chemoattractant and the
chambers were placed in an incubator at 37 °C and 5%
CO2 for 22 h. The cells that did not migrate through the
matrigel membrane were subsequently removed with a
cotton swab and the cells at the bottom of the mem-
brane were fixated, stained with crystal violet and
counted manually by bright field microscopy on an
inverted microscope (Leica DMI6000B).
Statistical analysis
Statistics were performed with GraphPad Prism version
7.02 (GraphPad Software Inc., La Jolla, CA, USA) using
ANOVA analysis followed by a Fisher LSD test. Results
are represented as mean ± standard error of mean (SEM)
in all experiments with three or more independent repli-
cates (mean ± standard deviation (SD) in experiments
with two independent replicates) and significance (only
calculated in experiments with at least three replicates)
was assumed if p ≤ 0.05.
Results
Doxycycline reduces MMP-2 activity and expression of
pro-MMP-2 in immortalized endometriotic cells (12Z)
Doxycycline treatment of 12Z epithelial endometriotic
cells reduced the detected activity of MMP-2 in a
dose-dependent manner in the MMP-2 activity assay
(Fig. 1a). To exclude cell mortality as a reason for re-
duced MMP-2 secretion, we performed viability assays.
We observed no significant cell mortality up to doses
of 20 μg/ml doxycycline, whereas 40 μg/ml doxycycline
led to a reduced number of viable cells (65% of the con-
trol, Fig. 1b). This means that the reduced levels of
MMP-2 up to 20 μg/ml were not due to reduced cell
numbers or increased mortality of endometriotic cells.
Reduced expression of latent MMP-2 (pro-MMP-2)
was found in a zymography assay upon treatment with
doxycycline (Fig. 1c and d).
Doxycycline reduces MMP-2 and MMP-9 activity and
expression of pro-MMP-2 and pro-MMP-9 in primary
endometriotic cells
Primary endometriotic stromal cells were obtained from
two different patients and extracted from endometriotic
tissue issuing from deep-ovarian endometriomas as de-
scribed above. Analysis of the presence of gelatinases by
zymography revealed high levels of latent MMP-2
(pro-MMP-2) and moderate levels of latent MMP-9
(pro-MMP-9) in the supernatants of both primary stromal
cell cultures (cell passage number: 2). Doxycycline treat-
ment led to a dose-dependent reduction of MMP-2 and
MMP-9 activity in the primary endometriotic cells (Fig. 2a
and c) on cell passage number 3. A reduction of
pro-MMP-2 and pro-MMP-9 levels in doxycycline-treated
primary endometriotic stromal cells (cell passage number
3) was observed in zymography analyses (Fig. 2b, d and e).
There were no microscopic signs of increased cell death
and same cell counts in primary stromal endometriotic
cells after treatment with doxycycline up to 10 μg/ml
compared to the control, whereas some signs of increased
cell death and reduced cell counts were observable in cells
treated with 20 μg/ml and more pronounced with 40 μg/
ml as shown in Fig. 2f.
Doxycycline inhibits the invasion of 12Z through matrigel
membranes
Using matrigel-coated invasion chambers, we observed a
reduced invasion of doxycycline treated 12Z endome-
triotic cells compared with the control. Treatment with
doxycycline at a concentration of 1 μg/ml reduced the
relative number of invading cells to 65% and 10 μg/ml
reduced the invasive fraction to 22% of the control
(Fig. 3a and b). EDTA 1mM was used as a positive con-
trol (Fig. 3c).
Combination treatment of progesterone and doxycycline
synergistically reduces the MMP-2 activity and expression
of pro-MMP-2 in 12Z
To assess a possible synergistic effect of doxycycline with
progesterone treatment, we treated 12Z with a combin-
ation of low-dose doxycycline (1 μg/ml) and progesterone
(10 nM). Addition of doxycycline to progesterone further
reduced levels of activated MMP-2 compared to proges-
terone or doxycycline alone (Fig. 4a). A further reduction
of pro-MMP-2 levels in progesterone treated 12Z upon
simultaneous treatment with doxycycline in a range of 1–
40 μg/ml was observed especially at low doxycycline doses
in zymography assays (Fig. 4b).
Discussion
Our results demonstrate that doxycycline inhibits
MMP-2 activity and expression of pro-MMP-2 in the
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Fig. 1 Doxycycline reduces active MMP-2 levels in 12Z endometriotic cells. a Determination of the active form of MMP-2 in doxycycline-treated
12Z endometriosis cells in an activity assay (Biotrak MMP-2 activity assay) which specifically binds MMP-2 in antibody-coated microwells followed
by repeated washing steps. The treatment with doxycycline reduced the active MMP-2 levels in a dose-dependent manner. The mean values of
three independent treatments are represented with the standard error of mean (SEM) and significance labeled as “α” if p≤ 0.05. b Cell viability
was assessed with trypan blue to exclude that reduced MMP-2 levels were due to increased cell death rates. As is shown in the figure,
concentrations of doxycycline up to 20 μg/ml did not lead to reduced cell viability. Representation of the mean and SEM, significant differences
(i.e. if p≤ 0.05) are labeled with an “α” next to the bar. c Representative illustration of a zymography gel (inverse picture) for detection of latent
and active gelatinase levels ((pro-)MMP-2 and -9). The analysis was performed in culture supernatants of immortalized 12Z endometriotic cells
treated with respective doses of doxycycline in serum-free medium for 24 h. Samples were loaded on an electrophoresis gel containing gelatin,
followed by an incubation for 24 h in a buffer medium containing zinc and calcium chloride at 37 °C. The molecular size of the detected bands
corresponds to pro MMP2 and the bands showed decreasing expression with increasing doses of doxycycline. Note the second band below pro
MMP2 corresponding to active MMP-2 which is not visible in the samples probably due to the very low amount compared to the latent form.
(Pro-)MMP-9 was not detectable in 12Z by gelatin zymography. rMMP-2 and -9: reconstituted lyophilized human pro-MMP-2 and pro-MMP-9. d
Quantification of pro-MMP-2 activity from two independent drug treatments. Representation of the mean and standard deviation (SD)
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supernatant of the 12Z epithelial endometriotic cell line
and of MMP-2/− 9 and pro-MMP-2/−9in the supernatant
of primary stromal endometriotic cells. Furthermore,
treatment with doxycycline reduced the invasion of im-
mortalized 12Z epithelial endometriotic cells through
matrigel membranes, which served as a model for the
basilar membrane of the peritoneum. The combination of
doxycycline and progesterone showed synergistical effects
in the reduction of MMP-2 expression in 12Z epithelial
endometriotic cells.
Fig. 2 Doxycyline treatment reduces active MMP-2 and -9 levels in primary stromal endometriotic cells. a and b Dose-dependent decrease of
latent and active MMP-2 levels following treatment with doxycycline as detected by zymography (a) and in an activity assay (b) in primary
stromal endometriotic cells. In contrast to the immortalized epithelial endometriotic cell line 12Z, MMP-9 was also detectable in the supernatants
of stromal endometriotic primary cell cultures. Similarly to MMP-2, treatment with doxycycline led to a dose-dependent decrease of active MMP-9
levels, examined by zymography (c) and in activity assays (d). Note that the activity assay specifically detects one MMP (− 2 or − 9) per assay by
specific antibody binding and several washing steps (i.e. washing out of potential interfering inhibitors or activators) in the antibody-coated
microwells, whereas zymography is performed by direct loading of the supernatants and therefore reflects the situation “as it is”. This is the
reason that both different methods were performed and are represented here. It also explains that the graphs of the different methods are not
identical. e Representative picture of a zymography gel loaded with the supernatant of primary cell cultures of endometriotic stromal cells
(inverse picture). The bands corresponding to pro-MMP-2 and -9 are clearly visible. Note the second band below corresponding to the activated
form of MMP-2 and -9 which is also very lightly visible in the untreated control. Doxycycline treatment led to a dose-dependent reduction of
levels of pro-MMP-2 and -9. Representation of the mean values and SD of two independent experiments. f Primary stromal cells were
automatically counted after treatment with doxycycline compared to the control. The number of adherent cells with normal microscopical shape
was identical up to 10 μg/ml of doxycycline compared to the control, whereas reduced cell numbers were counted when treated with 20 μg/ml
and 40 μg/ml, which microscopically correlated with more visible detached dead cells and cell debris
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Fig. 3 Doxycycline reduces the invasion of 12Z endometriotic cells in dose dependent manner. a Representative pictures of two matrigel
invasion assays: 12Z endometriotic cells were seeded into matrigel-coated invasion chambers and treated with respective doses of doxycycline in
serum-free medium. Serum-containing medium (DMEM containing 10% fetal bovine serum) was added to the lower chamber as a
chemoattractant and the invasion chambers were incubated for 22 h at 37 °C and 5% CO2. Subsequently, the invaded cells were fixed, stained
with crystal violet and counted using a microscope. The violet-stained endometriotic cells are clearly distinguishable from the much smaller,
unstained pores of the matrigel membrane. b Relative number of invaded cells compared to the untreated control. Result of two independent
experiments performed in duplicate each. c Control treatment with EDTA which inhibits the activity of gelatinases by binding of zinc. The results
are represented as mean ± SD
Fig. 4 Progesterone and doxycycline have an additive effect on the reduction of active and latent MMP-2 levels. a 12Z endometriosis cells with
either 10 nM progesterone (Prog) or 1 μg/ml doxycycline (Dox) or the simultaneous combination of both substances. The combination of low-
dose doxycycline (1 μg/ml) with progesterone (10 nM) showed an additive effect on the reduction of active MMP-2. b Already at a low dose
(1 μg/ml) doxycycline shows an additive effect to progesterone (10 nM) on inhibition of pro-MMP2. The results are represented as mean ± SD
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Increased MMP-2 and -9 activity is an important char-
acteristic of endometriotic cell infiltration as has been
demonstrated in several studies [5, 14, 21–23]. It has
been shown in other diseases that subantimicrobial-dose
doxycycline is a potent MMP-2 and -9 inhibitor and also
decreases expression of pro-MMP-2 and -9 [16, 17]. The
expected range of doxycycline in human plasma has
been reported at 1–3 μg/ml in pharmacokinetic studies
in adults with cystic fibrosis who received doxycycline
administered as an MMP inhibitor, a concentration
which corresponds to the dose range used in our in vitro
experiments [24]. We demonstrate in vitro, that a com-
bination of progesterone treatment with doxycycline can
considerably increase the efficacy of progesterone with
regards to inhibition of invasion of endometriotic cells.
To our knowledge, this is the first study proposing doxy-
cycline in combination with a progestogen as a treat-
ment for endometriosis.
However, a known limitation in endometriosis research
is that there are very few available cell line models which
only reproduce the epithelial or stromal cell component of
endometriosis at once and may not behave exactly like
endometriosis in vivo. This has also to be considered as a
limitation of the present study since the experiments were
principally done in the SV-40 transformed 12Z endome-
triotic cell line which is widely used in preclinical
endometriosis research but may not reflect all properties
of endometriotic cells in vivo. Therefore, further studies
should try to investigate the effect of doxycycline in com-
bination with a progestin in endometriotic models com-
bining the epithelial and stromal compartment and
therefore assessing its interactions or in vivo in animal
models. Another limitation is the fact that MMPs are
dependent on cyclic hormonal variations in vivo and that
also other factors such as growth factors, cytokines, and
metal ions are not likely to be present in exactly the same
amount in cell culture media as compared to human peri-
toneal fluid [9, 14].
Endometriosis is a chronic disease with frequent recur-
rence after surgical treatment. Although current hormonal
treatment options show good efficacy as recurrence
prophylaxis, a significant subset – especially of severe
forms of endometriosis – relapse under hormonal treat-
ment [4]. Combination of hormonal and non-hormonal
therapeutics may be an interesting option to enhance the
success rate of current medical endometriosis treatment.
Furthermore, a non-hormonal medical alternative is a fre-
quently manifested wish of patients with endometriosis in
the clinical practice. Patient preferences for an effective
and well tolerated therapeutic approach with less metabolic
effects are essential in the development of new drugs for
endometriosis [25].
In mouse models, doxycycline reduced the size of endo-
metriotic implants and immunohistochemical expression
of MMP-2 and MMP-9 in the peritoneal cavity of mice
[26]. Similar results were reported in a second in vivo
study using an experimental rat model [27]. Finally, a third
study in which a nanoparticle-assisted therapeutic ap-
proach was used, showed very promising results for doxy-
cycline in the treatment of endometriosis [28]. These
studies, together with our in vitro data, indicate a potential
use of doxycycline as a therapeutic option in endometri-
osis by direct inhibition of the gelatinase activity and re-
duction of the infiltrative potential in endometriosis.
However, clinical studies will be necessary to further
evaluate the potential use of doxycycline in the treatment
of endometriosis, also since there is no known ideal
non-primate animal model available to adequately reflect
the pathogenesis of human endometriosis.
To this date, no other studies except of the above
mentioned have investigated the effects of doxycycline
therapy in endometriosis with exception of clinical stud-
ies in which tetracyclines (or ethanol) were injected into
endometriotic cysts at high local concentrations for
sclerotherapy [29–31]. It is likely that the effect of this
treatment may be related to cell damage caused by ex-
tremely high local concentrations of doxycycline and this
treatment option appears obsolete nowadays. Neverthe-
less, it demonstrates the potential use of doxycycline in
the treatment of endometriosis. It has been demon-
strated that progestins reduce the expression and activity
of MMP-2 and MMP-9 in human endometrial explants
and the inhibitory effect of progesterone on the gelati-
nases MMP-2/− 9 has been proposed to be mediated by
the inhibition of plasminogen activators [19]. Therefore,
the additive effect of progesterone and doxycycline ob-
served in this study may be mediated through distinct
and complementary mechanisms that synergistically
inhibit the expression and activity of MMP-2.
The feasibility and good tolerability of long-term
subantimicrobial-dose doxycycline therapy has been
demonstrated in the treatment of other diseases such as
periodontosis, acne and rosacea. There were no reports of
problems with bacterial resistances in the dose level used,
and it is assumed that doxycycline does not exhibit anti-
biotic action in the low (i.e. subantimicrobial) doses used
for the purpose of inhibiting the gelatinases, such as
subantimicrobial-dose doxycycline (Periostat® 20mg) used
in periodontitis [32–35]. Severe allergic reactions are
reportedly to be extremely rare. Doxycycline hyclate
20 mg is contraindicated in nursing mothers, pregnant
women and pediatric patients due to potential te-
ratogenic effects and potential severe adverse effects
in children. Most of the adverse reactions in adults,
including headache, common cold and flu symptoms,
nausea, dyspepsia, joint pain and diarrhea, were
reported in similar frequency for doxycycline hyclate
20 mg and for placebo [36].
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From a clinical point of view a combination treatment
of doxycycline with a suitable progestin, such as e.g.
dienogest, for patients with severe forms of infiltrative
endometriosis that do not respond well enough to the
hormonal treatment alone, would be an interesting option.
This treatment option could possibly be used as a medical
prevention of a recurrence after surgical excision of
endometriosis. Although dienogest is assumed to inhibit
ovulation, an additional contraceptive barrier method would
be necessary for the duration of this treatment, as is cur-
rently recommended for the therapy with dienogest alone.
Conclusions
In conclusion, our results demonstrate the potential for use
of subantimicrobial-dose doxycycline in the treatment of
endometriosis in vitro and its synergistic action with pro-
gestins. Since subantimicrobial-dose doxycycline is a well
tolerated drug, it appears to be a potential treatment option
in endometriosis which may be further evaluated in clinical
research. The combination of doxycycline with current hor-
monal treatment forms may increase the efficacy of hormo-
nal treatment in endometriosis, which might be of interest
in e.g. severe forms of deep-infiltrating endometriosis which
are responding insufficiently to current treatment options.
In addition, subantimicrobial-dose doxycycline might be an
interesting alternative for patients who wish to have a
non-hormonal medical prevention of recurrence after
surgical excision of endometriosis.
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